Autoantibody Diversity Is Augmented in Women with Breast Cancer and Is Related to the Stage of the Disease.
Jesús Pérez-HernándezRosalba León-DíazAlejandro ZentellaEdmundo LamoyiMarcela Esquivel-VelázquezAntonia Barranca-EnríquezTania Romo-GonzálezPublished in: Current oncology (Toronto, Ont.) (2023)
Breast cancer (BC) is the most frequent malignant neoplasia and leading cause of cancer mortality for women. A timely diagnosis of BC is crucial to ensure the best chances of survival. Among the various screening tools for BC, antibodies directed towards self-antigens or tumor-associated antigens (autoantibodies) have emerged as an alternative to image-based screening modalities. However, little attention has been paid to the global diversity of autoantibodies. This work aimed to analyze the diversity of autoantibodies reactive to antigens expressed by the BC cell line T47D in the sera of Mexican women with BC, benign breast pathology (BBP), or without breast pathology (WBP). We found that the diversity of antibodies in the sera was higher in the BC and BBP groups than in the WBP group. Likewise, the diversity changed with the progression of BC. Our results show and measure the complexity of the antibody response in breast health and disease.
Keyphrases
- systemic lupus erythematosus
- dendritic cells
- public health
- healthcare
- squamous cell carcinoma
- deep learning
- pregnant women
- mental health
- metabolic syndrome
- machine learning
- risk assessment
- skeletal muscle
- adipose tissue
- immune response
- polycystic ovary syndrome
- coronary artery disease
- cardiovascular events
- pregnancy outcomes
- climate change
- young adults
- virtual reality
- insulin resistance